

---

### Author Correction: Single-dose suraxavir marboxil for acute uncomplicated influenza in adults and adolescents: a multicenter, randomized, double-blind, placebo-controlled phase 3 trial

---

Correction to: *Nature Medicine*  
<https://doi.org/10.1038/s41591-024-03419-3>,  
published online 7 January 2025.

<https://doi.org/10.1038/s41591-025-03541-w>

Published online: 31 January 2025

---

Yeming Wang, Hong Wang, Yu Zhang, Anlin Ma, Dong Liu, Xiaoguang Li, Guoru Yang, Min Deng, Shaofang Wang, Yuanyuan Liu, Chuanmiao Liu, Fangqi Ge, Sikui Wang, Yunsong Yu, Ganzhu Feng, Zuke Xiao, Xing Li, Yilan Sun, Xuyan Chen, Zhaolong Cao, Yan Ding, Xiaoping Wu, Jun Wei & Bin Cao 

In the version of the article initially published, in Fig. 1, the boxes “194 were assigned to the suraxavir group” and “1 did not receive suraxavir” should have read “194 were assigned to the placebo group” and “1 did not receive the placebo” and have now been corrected in the HTML and PDF versions of the article.

© The Author(s), under exclusive licence to Springer Nature America, Inc. 2025

---

### Author Correction: Mapping the effectiveness and risks of GLP-1 receptor agonists

---

Correction to: *Nature Medicine*  
<https://doi.org/10.1038/s41591-024-03412-w>,  
published online 20 January 2025.

<https://doi.org/10.1038/s41591-025-03542-9>

Published online: 31 January 2025

---

Yan Xie , Taeyoung Choi & Ziyad Al-Aly 

In the version of the article initially published, in the thirteenth paragraph of the Discussion, the sentence “the study included 1,032,192 (5.28%) women...” was incorrect and has now been amended to “the study included 103,219 (5.28%) women...” in the HTML and PDF versions of the article.

This is a U.S. Government work and not under copyright protection in the US; foreign copyright protection may apply 2025